Shanghai OPM Biosciences Co. Ltd.

Shanghai OPM Biosciences Co. has seen notable stock performance, with a significant increase on August 10, 2026. The company has outperformed the China Shanghai Composite over various timeframes, despite facing long-term growth challenges. Recent financial results show a positive turnaround in operating cash flow and net sales growth.

Shanghai OPM Biosciences Co. saw a notable stock price increase on July 10, 2026, amid a broader market decline. The company reported strong financial results for the first half of the year, including significant growth in net sales and operating cash flow, while facing challenges in long-term performance.

Shanghai OPM Biosciences Co. has seen a notable rise in stock performance, reaching an intraday high of CNY 45.11. The company reported a 37.97% increase in net sales for the first half of the year, alongside positive operating cash flow and net profit figures, despite longer-term challenges.

Shanghai OPM Biosciences Co. saw a notable increase in stock performance on June 29, 2026, outperforming the China Shanghai Composite. Despite recent gains and improved financial results, the company faces long-term challenges, including slow net sales growth and a significant decline in operating profit over the past five years.

Shanghai OPM Biosciences Co. faced notable declines on June 2, 2026, contrasting with the broader market's modest gains. The company has struggled with long-term growth, showing a significant drop in operating profit over five years, while its market capitalization is CNY 5,251 million with a high price-to-earnings ratio.

Shanghai OPM Biosciences Co. has experienced a recent evaluation adjustment, influenced by various financial metrics and trends. The company reported a significant operating cash flow and net sales growth in the latest quarter, although it continues to face long-term challenges in profitability and sales growth rates.

Shanghai OPM Biosciences Co. saw a notable decline in its stock today, contrasting with the broader market's performance. Despite reporting strong half-year net sales growth, the company faces challenges, including a significant drop in net profit over the past year, amid a tough market environment.

Shanghai OPM Biosciences Co. saw a notable stock increase on March 6, 2026, reaching an intraday high. However, the company has faced challenges, with declines over the past week and month, while maintaining a modest yearly return. Its market capitalization is CNY 5,991 million, indicating mid-cap status.